AI Article Synopsis
- - The study examined the effectiveness of ACEI and ARB medications on clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) during a contemporary reperfusion era.
- - Data from over 12,000 patients indicated that those who did not receive reperfusion treatment benefited significantly from ACEI/ARB therapy, experiencing lower rates of major adverse cardiac events and stroke.
- - Conversely, patients undergoing primary percutaneous coronary intervention (PCI) showed no significant difference in outcomes regardless of ACEI/ARB treatment, suggesting that these medications are more beneficial for those not receiving reperfusion therapy.
Article Abstract
Background: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) had beneficial effects on clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) in the pre-reperfusion or thrombolytic era. It is unknown if the benefits persist in the contemporary reperfusion era.
Objectives: We sought to determine if ACEI/ARB improves clinical outcomes of patients with STEMI in the contemporary reperfusion era according to the reperfusion strategy.
Methods: 12596 patients were analyzed from the prospective, nationwide, multicenter China Acute Myocardial Infarction (CAMI) Registry. These patients were classified into the no reperfusion group (n=6004) and the primary percutaneous coronary intervention (PCI) group (n=6592). Two-year all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE) were compared.
Results: In the no reperfusion group, ACEI/ARB therapy at discharge may reduce the incidences of 30-day MACCE (4.7% vs 7.4%; adjusted hazard ratio [HR]: 0.67; 95% confidence interval [CI]: 0.53-0.85; P<0.001), stroke (0.5% vs 1.1%; adjusted HR: 0.41; 95% CI: 0.21-0.83; P=0.01), and revascularization (2.1% vs 3.1%; adjusted HR: 0.66; 95% CI: 0.46-0.94; P=0.02) compared to patients not treated with ACEI/ARB. Patients treated with ACEI/ARB also showed a lower rate of two-year MACCE (17.0% versus 19.1%; adjusted HR: 0.87; 95% CI: 0.76-0.99; P=0.04). No differences were observed in the remaining outcomes. In the primary PCI group, no differences were observed for all examined outcomes before and after multivariate adjustments.
Conclusions: Treatment with ACEI/ARB at discharge may reduce cardiovascular events in STEMI patients not receiving reperfusion, while no significant benefits were observed in those receiving primary PCI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.33963/v.phj.102772 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Approaches to Optimize Donor Heart for Transplantation.
J Heart Lung Transplant
December 2024
Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, USA.
Heart transplantation remains a critical therapy for patients with end-stage heart failure, offering incremental survival and improved quality of life. One of the key components behind the success of heart transplantation is the condition and preservation of the donor heart. In this review, we provide a comprehensive overview of ischemic reperfusion injury, risk factors associated with primary graft dysfunction, current use of various preservation solutions for organ procurement and recent advancements in donor heart procurement technologies.
View Article and Find Full Text PDFImpact of diabetes on epicardial reperfusion and mortality in a contemporary STEMI population undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry.
Nutr Metab Cardiovasc Dis
October 2024
Division of Cardiology, Ospedale degli Infermi, ASL Biella, Italy.
Background And Aim: Diabetes has been shown in last decades to be associated with a significantly higher mortality among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI (PPCI). Therefore, the aim of current study was to evaluate the impact of diabetes on times delays, reperfusion and mortality in a contemporary STEMI population undergoing PPCI, including treatment during the COVID pandemic.
Methods And Results: The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry involving PPCI centers from Europe, Latin America, South-East Asia and North-Africa, including patients treated from 1st of March until June 30, 2019 and 2020.
Prevalence and clinical outcomes of acute myocardial infarction in patients presenting with major trauma.
Injury
October 2024
Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Article Synopsis
- The study investigates acute myocardial infarction (AMI) in major trauma patients, which is often overlooked in both trauma and cardiology fields.
- Using data from the Victorian State Trauma Registry from 2013 to 2022, researchers focused on patients with significant injuries and examined their clinical outcomes related to AMI.
- They found that 1.4% of trauma patients experienced AMI, typically in older individuals with more health issues, leading to longer hospital stays and higher mortality rates compared to those without AMI.
Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine.
Cureus
October 2024
Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, USA.
Article Synopsis
- - Hemorrhage is the main cause of preventable death in trauma situations, leading to military and civilian advancements in medical practices, particularly through the use of tourniquets to manage extremity bleeding and save lives.
- - While tourniquets have significantly decreased deaths from bleeding in military settings, noncompressible hemorrhage still poses a major risk, especially before patients receive definitive medical care.
- - The study explores using a small, disposable pressure monitor during resuscitative endovascular balloon occlusion of the aorta (REBOA) to enhance blood pressure monitoring, facilitate better resuscitation practices, and reduce the need for blood products in extreme environments.
Hepatic ischemia-reperfusion injury (HIRI) is a major complication reported in various clinical scenarios such as liver transplantation (LTx), hepatectomy, and acute hepatic insult. This condition affects the restoration of hepatic functionalities post-LTx. Contemporary scientific inquiries have highlighted the involvement of intestinal microbiota and their metabolic by-products in the initiation and progression of HIRI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!